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Abstract: Celiac disease is characterized by a chronic immune-mediated inflammation of the small
intestine, triggered by gluten contained in wheat, barley, and rye. Rothia aeria, a gram-positive natural
colonizer of the oral cavity and the upper digestive tract is able to degrade and detoxify gluten
in vitro. The objective of this study was to assess gluten-degrading activity of live and dead R. aeria
bacteria in vitro, and to isolate the R. aeria gluten-degrading enzyme. Methods: After an overnight
fast, Balb/c mouse were fed a 1 g pellet of standard chow containing 50% wheat (and 4% gliadin)
with or without 1.6 × 107 live R. aeria bacteria. After 2 h, in vivo gluten degradation was assessed
in gastric contents by SDS-PAGE and immunoblotting, and immunogenic epitope neutralization
was assessed with the R5 gliadin ELISA assay. R. aeria enzyme isolation and identification was
accomplished by separating proteins in the bacterial cell homogenate by C18 chromatography
followed by gliadin zymography and mass spectrometric analysis of excised bands. Results: In mice
fed with R. aeria, gliadins and immunogenic epitopes were reduced by 20% and 33%, respectively,
as compared to gluten digested in control mice. Killing of R. aeria bacteria in ethanol did not
abolish enzyme activity associated with the bacteria. The gluten degrading enzyme was identified
as BAV86562.1, here identified as a member of the subtilisin family. Conclusion: This study shows
the potential of R. aeria to be used as a first probiotic for gluten digestion in vivo, either as live or
dead bacteria, or, alternatively, for using the purified R. aeria enzyme, to benefit the gluten-intolerant
patient population.
Keywords: celiac disease; epitope; Rothia; Bacillus; gluten; degradation; subtilisin; commensal;
detoxify; neutralize; cure
1. Introduction
Gluten is found in wheat, barley, and rye and triggers celiac diseases (CeD), a chronic inflammatory
immune-mediated disease affecting the (proximal) small intestine [1]. Globally, CeD can be found in
0.5 up to 2% of wheat consuming populations [2]. Immunogenic gluten proteins show an unusual
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resistance to degradation by human digestive enzymes and are antigenically presented on human
leukocyte antigen (HLA) DQ2 or DQ8 that are expressed on myeloid and B cells in the intestinal lamina
propria, triggering a gluten peptide specific T helper 1 (Th1) T cell response [3,4]. Immunogenicity
(toxicity) associated with gluten is peptide length-dependent, where peptides shorter than 9 residues
are unable to generate an immune response [5–7]. Therefore, detoxification of gluten peptides can be
achieved by their extensive proteolytic fragmentation to smaller gluten moieties.
The microbiome colonizing the oral cavity is a rich source of proteolytic enzymes. The oral
cavity is also the port of entry where ingested food contents are mixed with saliva and reach the more
downstream regions of the gastrointestinal tract. The oral microbiome comprises over 700 different
microbial species or phenotypes [8,9]. Saliva harbors over 100 million bacterial cells per milliliter.
In fact, the oral cavity is, after the colon and the cecum, the most densely colonized part of the human
gastrointestinal tract [10]. The functions and properties of many individual species within these mixed
culture microbiomes remain unknown. Furthermore, the potential contribution of, e.g., oral microbial
species to physiological processes in the digestive tract is virtually unknown.
We recently showed that oral Rothia bacteria produce enzymes that degrade dietary gluten proteins
in vitro [3]. This finding of an oral (and gastric) microbe digesting an essential food constituent points
to potentially novel functions for oral microorganisms in digestion, having implications beyond the
oral cavity. The Rothia genus, formerly called Stomatococcus, comprises several species, including
R. aeria, R. mucilaginosa, and R. dentocariosa. They are Gram-positive microbes that thrive well in
the oral environment. R. mucilaginosa has also been detected at low levels in the duodenum [11].
Little is known on the functional role that Rothia species play in the oral cavity, other than that they are
mostly associated with oral health [12]. Here, the discovery of the gluten-degrading capabilities of
Rothia bacteria added to the potential beneficial activity of this commensal. Furthermore, the fact that
R. mucilaginosa and R. aeria species [13–15] degrade gluten suggests they may be useful in the treatment
of CeD, which is triggered by incompletely digested gluten peptides.
The purpose of the present study was three-fold. First, to investigate the gluten degrading and
epitope neutralizing activity of R. aeria in vivo; second, to assess if R. aeria bacteria would retain
enzymatic activity after the bacteria are killed; and third, to isolate and identify the gluten-degrading
enzyme from R. aeria.
2. Materials and Methods
2.1. In Vivo Digestion Experiment
Cultivation of R. aeria bacteria—Rothia aeria strain WSA-8 [15] has been deposited as strain
HM-818 to the BEI resources (beiresources.org) and has been sequenced. It is equivalent to R. aeria
Oral Taxon 188, strain F0474 (HMP ID 1324). R. aeria bacteria were grown on Brucella agar plates
(Hardy Diagnostics, Santa Maria, CA, USA) at 37 ◦C for 48 h under aerobic conditions. The cells were
harvested from the plate with a cotton swab and suspended in sterile PBS to an OD620 180. Aliquots
of 1.5 mL of the suspension were centrifuged and the supernatants were removed. The cell aliquots
comprising approximately 1.59 × 107 cells/mL were lyophilized in a SpeedVac and stored at −80 ◦C.
Preparation of mouse chow admixed with Rothia bacteria—Mouse chow (2018, Envigo,
Cambridgeshire, UK) with bacteria was prepared in advance of the in vivo experiment. The chow used
contains approximately 18% crude protein. An aliquot of 1 g of mouse chow, containing 50% wheat as
protein source, containing roughly 10% of gluten and 8% gliadin, approximately 25 mg of gliadin was
dry mixed with lyophilized R. aeria bacteria at a ratio of 1.6 × 107 cells/gram chow. The mixture of
Rothia bacteria and chow were added to a 2 mL Eppendorf tube and water was added incrementally in
less than 1 min to form a slurry. The chow slurry was dried in the SpeedVac (SpeedVac plus SC110 A,
Savant, NY, USA) for 3 h during which the slurry was frozen. The resultant pellet was removed from
the Eppendorf tube and was visually similar to an original chow pellet.
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In vivo digestion by Rothia bacteria—Nine-week-old female Balb/c mice (n = 9 mice/group) were
fasted for 24 h and then fed 1 g of mouse chow with and without added R. aeria bacteria. Mice in both
groups ingested the chow within 1 h and then were allowed to digest the chow for an additional 2 h.
Stomach and (proximal) small intestine were harvested. Stomach and small intestinal contents were
collected and centrifuged (2000× g, ×10 min, Thermo Scientific legend X1R, USA). The supernatants
were collected and boiled (100 ◦C, 10 min), then mixed with 60% ethanol to extract the gliadins by
shaking (40 rpm) at room temperature for 1 h and centrifuged (2000× g× 10 min, 4 ◦C). The supernatants
were collected, and protein concentrations determined with the BCA protein assay.
Gliadin degradation—Since approximately one third of the food protein were found in the
small intestine and two thirds in the stomach, and only negligible amounts of gliadin in chow
were found in the small intestine (with less than 10% of the gliadin that were detectable in the
stomach), gliadin degradation was only assessed in the harvested stomach samples by SDS PAGE
and immunoblotting using a rabbit polyclonal anti-gliadin-peroxidase conjugated antibody produced
(Sigma A1052-1ML). Densitometric analysis of the obtained signals was carried out by drawing equal
size boxes around the bands in the gel of 37 kDa and 50 kDa bands, representing the α/β and γ gliadins,
respectively. The data were corrected for intensity level after subtracting the background by selecting a
blank area in the image on the different gels. The data from the various gels were normalized to 5 µg
of gliadin (provider) loaded on each gel. Analyses of band intensities were carried out using Quantity
one software.
Gliadin epitope neutralization—Hydrolysis of gliadin immunogenic epitopes in the harvested
stomach contents was assessed with the R5 ELISA assay (RIDASCREEN Gliadin-R-Biopharm AG
#R7001, Darmstadt, Germany) that measures an immune dominant omega-gliadin epitope. The protein
concentration of the stomach samples was adjusted to 160 µg/mL, and diluted 3200-fold in dilution
buffer, securing linearity in relation to the standard curve. Aliquots of 100 µL of each of the diluted
samples, as well as the controls of the 0 ppb and 80 ppb gliadin standard solutions included in the kit,
were added to each well. The assay was conducted according to the manufacturer’s instructions.
2.2. In Vitro Gliadin Digestion by Live and Dead Rothia Bacteria
R. aeria and R. mucilagiosa cell killing—The two oral isolates, R. mucilaginosa ATCC 25296 and
R. aeria (strain WSA-8) were cultured on Brucella agar plates, harvested and diluted in triplicate to an
OD620 of 1.2 in either 1 mL of 70% ethanol or in 1 mL of saliva ion buffer (SIB), containing 50 mM
KCl, 1.5 mM potassium phosphate, 1 mM CaCl2 and 0.1 mM MgCl2, pH 7.0. The bacterial cell
suspensions were incubated for 30 min at 37 ◦C and 5 µL aliquots were plated in triplicate on Brucella
agar. The residual 995 µL aliquots were lyophilized to dryness using a SpeedVac (Thermo Fisher,
Waltham, MA, USA). The lyophilized bacteria in 70% ethanol were reconstituted in 1 mL sterile SIB,
and the lyophilized bacteria in SIB were reconstituted in deionized sterile water, to obtain the same
final ion composition in both samples. The reconstituted cell samples were used to determine gliadin
degrading enzyme activity.
In gel gliadin degradation—Zymogram gels (6%) were prepared using gliadin from wheat
(Sigma, St. Louis, MO, USA) as the gel-incorporated substrate, as previously described [16]. In brief,
bacteria from the above reconstituted suspensions equivalent to 600 µl, were harvested, suspended in
30 µL zymogram sample buffer, and loaded onto a zymogram gel. Electrophoresis was carried out
at 100 V at 4 ◦C, and gels were renatured and developed in zymogram renaturing and developing
buffers (InVitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. After 48 h of
development at 37 ◦C, gels were stained with 0.1% Coomassie Brilliant Blue as described [16].
Synthetic tripeptide substrates hydrolysis—In a 96 well microtiter plate aliquots of 200 µL
aliquots of the reconstituted Rothia aeria and R. mucilaginosa cell suspensions were mixed with 20 mM
Z-Tyr-Pro-Gln-pNA (Z-YPQ-pNA) (21st Century Biochemicals, Marlborough, MA, USA). The final
substrate concentration was 200 µM. All experiments were performed in triplicate. Substrate hydrolysis
was monitored spectrophotometrically at 405 nm, using a Genios microtiterplate reader (Tecan Group
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Ltd., Männedorf, Switzerland) and Deltasoft software, with the equipment temperature set at 37 ◦C.
Readings were performed in the kinetic mode at selected time intervals to capture the linear part of the
conversion curve.
2.3. Isolation and Identification of the Gluten-Degrading Enzyme from R. aeria
To identify the gluten-degrading enzyme produced by R. aeria, the bacteria were cultured on
Brucella agar plates (Hardy Diagnostics, Santa Maria, CA, USA) at 37 ◦C for 48 h under aerobic
conditions. The cells were harvested from the plate with a cotton swab and suspended in sterile PBS to
an OD620 5.0. Four aliquots of 1.5 mL of the suspension were centrifuged (2000× g, 10 min, 4 ◦C) and
the supernatants were removed.
SDS-PAGE and casein zymography—The four cell pellets were re-suspended each in 200 µL
zymogram sample buffer [13], and subject to a non-reducing (no DTT or β-mercaptoethanol-containing)
6% SDS-PAGE gel of 16 × 20 × 0.15 cm, using a protean II xi cell system (Bio-Rad, Hercules, CA,
USA). The composition of this gel was the same as that of previously published 6% gliadin zymogram
gels but without incorporation of gliadin [13]. After electrophoresis at a constant voltage of 120 V
at 4 ◦C, the gel was divided in two halves. The first half was stained with 0.1% Coomassie Brilliant
Blue in 40% (v/v) methanol/10% (v/v) acetic acid. The second half was developed as a zymogram gel
to reveal enzyme activity associated with the bands [14]. To this effect, the zymogram gel half was
washed twice for 30 min in buffer containing 2.5% Triton X-100 (renaturing buffer; Life Technologies,
Carlsbad, CA, USA), followed by washing twice for 1 h in buffer containing 20 mM Tris-HCl, pH 7.5
(developing buffer; Life Technologies, Carlsbad, CA, USA). Gel A was then incubated in developing
buffer supplemented with 1% casein (Sigma, St. Louis, MO, USA) at 37 ◦C for 1.5 h, followed by a
washing step for 2 min and staining with 0.1% (w/v) Coomassie Brilliant Blue in 40% (v/v) methanol/10%
(v/v) acetic acid for 24 h. Both gel halves were then de-stained in 40% (v/v) methanol/10% (v/v) acetic
acid until optimal contrast was achieved.
LC-ESI-MS/MS—The gel halves described above were aligned, and the proteins displaying enzyme
activity were excised. The proteins were digested in-gel with sequencing-grade trypsin, and the
peptides were eluted and separated by in-line C18 chromatography, as previously described [14].
In brief, the amino acid sequences of the peptide ions were obtained with an LTQ Orbi-trap mass
spectrometer (ThermoFinnigan, San Jose, CA, USA). The b- and y-ion spectra were searched against
a database of R. aeria F0474, supplemented with decoy proteins as well as the three Rothia subtilisin
genes published previously [14]. The filter settings selected were X-corr values > 2.2 and 3.5 for Z = 2,
and 3, respectively. The deltaCn and peptide probability settings were >0.1 and <0.01, resp.
Statistical analysis—The in vivo digestion data were analyzed using SPSS 17.0 software and
computed with GraphPad Prism 8. The non-parametric Mann–Whitney test was used to test for
statistical significance between groups. The data are represented as the average ± standard error of the
mean (SEM), and a value of p < 0.05 was considered to be statistically significant.
3. Results
3.1. In Vivo Digestion by life Rothia Bacteria
Mice were fed chow with and without R. aeria bacteria, and digestion of the gluten was monitored
in samples removed from the digestive tract. During preparation of the chow/R. aeria mixture, gliadin
remained intact (Supplemental Figure S1, lanes 2 and 5). In mice fed the chow/R. aeria mixture, after 2 h
of digestion, most of the chyme was present in the stomach, as evidenced by total protein determination
(Figure 1A), SDS page (Figure 1B; left panel) and anti-gliadin immunoblotting (Figure 1B, right panel)
of samples harvested from the stomach, duodenum, jejunum, and ileum.
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Figure 1. Analysis of gastric and small intestinal contents. A, Total protein content of the stomach contents (red) and small intestine (orange); n=4 per organ; prtein
was determined by the BCA method multiplied by sample volume and divided by the total protein in both the stomach and intestine. B, Analysis of gliadin in gastro-
intestinal samples by SDS-PAGE (left panel) and anti-gliadin immunoblotting (right panel). Aliquots (63 µg protein) of the gastro-intestinal samples with R. aeria (Ra+)
and without (Ra-) bacteria were loaded on two 4-12% SDS-PAGE gels. After electrophoresis at 120 V, the gels were either stained with Coomassie brilliant blue (left) or
processed by immunoblotting with an anti-gliadin antibody (right). Lanes 1: Protein standard, 5 µl; 2: Gliadin control (Gli, 25 µg); 3: stomach Ra (-);4: stomach Ra (+);5:
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Figure 1. Analysis of gastric and small intestinal contents. (A) Total protein content of the contents
in the stomach (red) and small intestine (orange); n = 4 per organ; protein was determined by the
BCA method multiplied by sample volume and divided by the total protein in both the stomach
and intestine. (B) Analysis of gliadin in gastro-intestinal samples by SDS-PAGE (left panel) and
anti-gliadin immunoblotting (right panel). Aliquots (63 µg protein) of the gastro-intestinal samples
with R. aeria (Ra+) and without R. aeria (Ra−) bacteria were loaded on two 4–12% SDS-PAGE gels.
After electrophoresis the gels were either stained with Coomassie brilliant blue (left) or processed by
immunoblotting with an anti-gliadin antibody (right). Lanes 1: Protein standard, 5 µL; 2: Gliadin
control (Gli, 25 µg); 3: stomach Ra (−);4: stomach Ra (+);5: duodenum Ra (−);6: duodenum Ra (+);
7: Jejunum Ra (−);8: jejunum Ra (+); 9: ileum Ra (−); 10: ileum Ra (+). Arrows: gliadin bands at
37 and 50 kDa.
The in vivo digestion experiments were carried out with 9 female mice per group. After an
overnight fast, the control and experimental groups were fed chow without and with R. aeria for 1 h,
respectively, and euthanized 2 h thereafter. All mice ingested the chow within 1 h, and therefore,
the effective digestion time was 2 h. Gliadin levels in the stomach samples from mice fed with and
without R. aeria were determined from the densitometric analysis of the major gliadin bands at 37 and
50 kDa in sample aliquots normalized to for total protein content (Figure 2A). The gliadin amount
significantly decreased in the Ra (+) group compared to Ra (−) group (Figure 2B).
To investigate the survival of immunogenic epitopes in the harvested stomach samples, an ELISA
test was carried out using R5 monoclonal antibody, specifically recognizing the QQPFP, QQQFP,
and LQPFP immunogenic epitopes [13,17]. The average values for the mice fed with chow supplemented
with R. aeria was 16.8 ± 0.15 ppm (OD 0.63) compared to 25.1 ± 0.23 ppm (OD 0.88) for the control
group. This reduction of the gliadin immunogenic epitopes as detected by ELISA is therefore in accord
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with the western blot results, showing a statistically significant reduction of 32.6% as compared to the




Figure 2. Gliadin degradation in vivo by Rothia bacteria. (A) Two groups of mice (M) were fed chow 
without R. aeria and chow with R. aeria. Aliquots (160 µg protein) of the gastric samples with (Ra+) 
and without (Ra−) bacteria (n = 9/group) were subjected to immunoblotting with an anti-gliadin 
antibody. Lane 1, 2, 3; 10, 11, 12; 19, 20, 21: Gliadin control (5, 1 and 0.2 µg), respectively; Lanes 4, 6, 
8, 13, 15, 17, 22, 24, 26: the nine mice fed chow without R. aeria bacteria Ra (−); Lanes 5, 7, 9, 14, 16, 18, 
23, 25, 27: the nine mice fed chow with R. aeria bacteria Ra (+). The blue (arrow) pointed to the gliadin 
bands at 37 kDa. (B) Densitometric analysis of the major gliadin protein bands (shown in A); data 
points represent the average of the remaining gliadin amount (AU). The data represent three 
independent experiments and the error bars ± SEM. * p < 0.05. C, R5 epitope levels, expressed in 
OD450nm, in stomach samples from mice fed chow supplemented with R. aeria (Ra+) and without R. 
aeria (Ra−). The data are representative of three independent experiments and the error bars represent 
the average ± SEM. ** p < 0.01. 
3.2. In Vitro Gluten Digestion by Dead Rothia Bacteria  
In view of the concern that some probiotics, even if they represent harmless colonizers, might 
favor opportunistic infections in immunocompromised hosts, we investigated if the cell-associated 
enzyme activities were maintained after abolishing the viability of Rothia bacteria. To achieve cell 
killing with an agent that can be removed after treatment, R. mucilaginosa ATCC 25296 and R. aeria 
(WSA-8) bacteria were incubated in 70% ethanol or in saliva ion buffer (SIB, control). After 30 min of 
incubation, cell viabilities were determined by plating aliquots of the ethanol or SIB-treated cells in 
triplicate on agar (Figure 3A). Enzyme activities in the ethanol or SIB-incubated cell suspensions were 
evaluated qualitatively by zymography (Figure 3B), and quantitatively with the tripeptide substrate 
Z-YPQ-pNA (Figure 3C). The maximum rates of Z-YPQ-pNA hydrolysis are depicted in Figure 3D. 
Results showed complete loss of cell viability for both strains after incubation with 70% ethanol, but 
not with SIB (Figure 3A). Remarkably, enzyme activities were maintained, as evidenced from clear 
bands in the zymogram of the ethanol treated and untreated samples (Figure 3B). The tripeptide 
hydrolysis rates depicted in Figures 3C, and 3D, show that on average less than 10% of the enzyme 
Figure 2. Gliadin degradation in vivo by Rothia bacteria. (A) Two groups of mice (M) were fed chow
without R. aeria and chow with R. aeria. Aliquots (160 µg protein) of the gastric samples with (Ra+) and
without (Ra−) bacteria (n = 9/group) were subjected to immunoblotting with an anti-gliadin antibody.
Lane 1, 2, 3; 10, 11, 12; 19, 20, 21: Gliadin control (5, 1 and 0.2 µg), respectively; Lanes 4, 6, 8, 13, 15, 17,
22, 24, 26: the nine mice fed chow without R. aeria bacteria R (−); L nes 5, 7, 9, 14, 16, 8, 23, 25, 27:
the nine mice fed chow with R. aeria bacteria Ra (+). The blue (arrow) pointed to the gliadin bands
at 37 kDa. (B) Densitometric analysis of the major gliadin protein bands (shown in A); data points
represent the average of the remaining gliadin amount (AU). The data represent three independent
experiments and the error bars ± SEM. * p < 0.05. (C), R5 epitope levels, expressed in OD450nm,
in stomach samples from mice fed chow supplemented with R. aeria (Ra+) and without R. aeria (Ra−).
The data are representative of three independent experiments and the error bars represent the average
± SEM. ** p < 0.01.
3.2. In Vitro Gluten Digestion by Dead Rothia Bacteria
In view of the concern that some probiotics, even if they represent harmless colonizers, might
favor opportunistic infections in immunocompromised hosts, we investigated if the cell-associated
enzyme activities were maintained after abolishing the viability of Rothia bacteria. To achieve cell
killing with n agent that can b removed after treatment, R. mucilaginosa ATCC 25296 and R. aeria
(WSA-8) ba teria were incubated i 70% e hanol or in saliva ion buffer (SIB, control). After 30 min of
incubation, cell viabilities were determined by plating aliquots of the ethanol or SIB-treated cells in
triplicate on agar (Figure 3A). Enzyme activities in the ethanol or SIB-incubated cell suspensions were
evaluated qualitatively by zymography (Figure 3B), and quantitatively with the tripeptide substrate
Z-YPQ-pNA (Figure 3C). The maximum rates of Z-YPQ-pNA hydrolysis are depicted in Figure 3D.
Results showed complete loss of cell viability for both strains after incubation with 70% ethanol, but not
with SIB (Figure 3A). Remarkably, enzyme activities were maintained, as evidenced from clear bands in
the zymogram of the ethanol treated and untreated samples (Figure 3B). The tripeptide hydrolysis rates
depicted in Figure 3C,D, show that on average less than 10% of the enzyme activity was lost following
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70% ethanol treatment. Overall, the method was an effective, food security compatible approach to
abolish bacterial viability without impairing the desired gluten-degrading enzyme activities.
Figure 3. Gliadin epitope degradation by R. mucilaginosa and R. aeria bacteria incubated in SIB or
ethanol. The bacterial cells were suspended in salivary ion buffer (SIB, pH 7.0) or 70% ethanol (EtOH)
to a final suspension cell density at OD620 of 1.2, and incubated at room temperature for 30 min.
After lyophilization and reconstitution, cell viability, and enzyme activities were determined. (A) Cell
viability assessed by plating 5 µL aliquots in triplicate on BA. (B) Cell associated enzyme activities
determined by gliadin zymography (zoom of enzyme active band only). (C) hydrolysis plots of Z-YPQ
pNA (Rothia strains). (D) Average maximum substrate hydrolysis rates derived from data in (C).
Left, R. mucilaginosa ATCC 25296; right, R. aeria WSA-8.
3.3. Isolation and Identification of the Gluten-Degrading Enzyme from R. aeria
To identify the gluten-degrading enzyme from R. aeria, a large SDS gel (16 × 20 cm) was used
for optimal protein separation. A low percentage gel (6%) facilitated separation of proteins with
molecular weights > 50 kDa. From our previous study it was known that the R. aeria enzyme migrated
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at approximately 75 kDa [15]. As an externally added substrate, casein instead of gliadin was added.
Casein has a better solubility than gliadin and can be used as alternative substrate to reveal the
gliadin-degrading enzymes in zymogram gels, giving a better contrast than gliadin [14,18].
The zymogram provided evidence for a single band migrating at ~75 kDa with enzyme activity,
and the matching non-denaturing Coomassie-stained gel showed a major band migrating at the same
position (Figure 4A,B). As a control, proteins were also analyzed on a denaturing gel, showing the full
spectrum of proteins migrating into the gel under these conditions (Figure 4C). The bands labeled 1–4
in Figure 4A,B were excised and subjected to mass spectrometric analysis. They were searched against
a R. aeria database, comprising protein entries derived from the whole genome of R. aeria as well as
protein entries from R. mucilaginosa and R. dentocariosa subtilisin genes.
As expected, more than one protein was identified in each band. In total 3, 4, 23, and 23 proteins
were identified by >2 unique peptides in bands 1, 2, 3, and 4, respectively. The most prominent
protein in all four samples, identified with high confidence, was peptidase S8, KGJ00122.1. It was
represented by 32, 30, 33, and 41 unique peptides, in the four excised bands, resp. A blast search of
KGJ00122.1 revealed that it is 99% homologous to a R. aeria protein annotated as glycerol-3P-ABC
transporter in NCBI (BAV86562.1). Sequence analysis of BAV86562.1 revealed that it is a subtilisin
family member, because it contains the cd07474 domain that is characteristic of the peptidase S8 family
domain. The sequence and the D, S, and H amino acids of the catalytic triad present in this peptidase
domain are shown in Supplementary Figure S3.
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There is a great interest among CeD patients in a medical therapy that can ameliorate gluten-
induced adverse effects that can also occur with trace amounts that celiacs may ingest with a 
supposed gluten free diet (GFD). A pharmacological therapy should eliminate the effect of milligram 
quantities up to a few grams of gluten in a largely GFD that avoids overt gluten sources, such as 
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Figure 4. Identification of the gluten degrading enzyme from R. aeria. (A) Gel part developed as a
zymogram gel using externally added casein as the enzyme substrate to visualize bands with enzyme
activity (indicated with an arrow). (B) Native PAGE gel part stained with Coomassie brilliant blue.
(C) SDS-PAGE mini gel stained with Coomassie brilliant blue. Bands 1–4 were excised and subjected to
mass spectrometric analysis.
4. Discussions
While oral bacteria are present in high amounts and in a wide variety in the oral cavity,
being swallowed in large numbers daily, their roles beyond the oral cavity are not well understood.
In the first part of the present work, we demonstrated that Rothia species can degrade dietary proteins,
specifically gluten, in vitro, as well as in vivo. This suggests that this species, and perhaps some other
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oral microbes as well, may play a role in the initiation of the digestion of these protein components
of foods.
There is a great interest among CeD patients in a medical therapy that can ameliorate
gluten-induced adverse effects that can also occur with trace amounts that celiacs may ingest with a
supposed gluten free diet (GFD). A pharmacological therapy should eliminate the effect of milligram
quantities up to a few grams of gluten in a largely GFD that avoids overt gluten sources, such as bread,
pizza, pasta, or cookies. Most CeD patients agree that such a diet would be much more sustainable,
since the required strictly gluten free diet (less than 20 ppm of gluten in all foods, i.e., less than
20 mg/kg) is a great challenge in everyday life [19]. Thus, in a double blind clinical study, CeD patients
in remission who were challenged with 50 mg gluten daily developed an average 20% decrease in
villous height/crypt depth vs. placebo within 90 days [20], indicating that such minor amounts of
gluten can cause chronic mucosal damage. In addition, a high sensitivity to minor amounts of gluten
may underly refractory celiac disease type 1.
A major therapeutic approach to such supportive therapy is the use of bacterial of grain-derived
gluten-degrading enzymes, first spearheaded by the group of Khosla [4,21–26] while commercially
available “glutenases” have no or little proven efficacy to effectively degrade antigenic gluten
peptides [26,27]. R. aeria is a gram-positive bacterium belonging to the Rothia genus and a natural
colonizer of the oral cavity, similar to R. mucilaginosa and R. dentocariosa. R. aeria exhibits a superior
gliadin degrading activity compared to R. mucilaginosa [15]. The finding suggests that Rothia species,
in particular R. aeria, as nonpathogenic human colonizers, may be considered as promising new
candidates for enzyme therapeutics in CeD.
Gliadin degradation is dependent on the amount of bacteria, the amount of gluten protein, the food
matrix, pH, and incubation time. With regard to the bacterial count, we found that R. aeria exerted
gliadin degradation in a dose dependent manner. Based on in vitro studies employing various ratios
of bacteria and gliadin, a dose of 1.6 × 107 CFU/g of chow was selected for the in vivo study. This dose
is not unrealistic, considering that probiotic applications can contain as high as 1011 up to 1012 CFU per
application [28]. Given the body weight of mouse of about 20 g, the dose calculated for a 70 kg human
would be (1.6 × 107 × 20 × 3500 = ~1012). The time between the end of the 1 h chow feed and sacrifice
of the mice was 2 h. The selected time span was based on a report that assessed the gastrointestinal
transit time in mice with 99mTc-DTPA-labeled activated charcoal. Within 2–3 h the labelled material
was detected in the stomach and the entire small intestine [29]. Therefore, 2 h digestion including a 1 h
complete ingestion of the food pellet was selected for the in vivo experiments.
Effective gastric digestion is essential before immunogenic gluten peptides reach the proximal
small intestine where they can elicit celiac disease. Therefore, we focused on gastric gliadin digestion.
The in vivo experiment with nine mice per group showed that R. aeria bacteria significantly reduced
the amount of intact gliadin molecules in the stomach before they reached the duodenum. Importantly,
this reduction was paralleled by a significant disappearance of major immunogenic gliadin epitopes as
assessed with the R5 gliadin ELISA. Rizzello et al. have demonstrated the efficiency of wheat dough
fermentation with Lactobacilli and fungal proteases using a similar approach in vitro [30].
Gluten-degrading microbes, especially if they are natural colonizers of the human body, are of
high interest for exploitation as treatments of CeD, since they carry the potential to be explored in
the form of probiotics [26]. Highly effective prolyl- and glutamine-endopeptidases for degradation
of immunogenic gluten epitopes are produced by various microorganisms. However, some of the
discovered gluten-degrading microbes are opportunistic pathogens and/or demonstrate associations
with human diseases. Thus, several gluten-degrading natural colonizers of the human body are not
necessarily harmless. Examples are Capnocytophaga sputigena, Neisseria mucosa, or Pseudomonas species,
which rapidly cleave immunogenic gluten domains, yet have been implicated in periodontal [31–33] and
endodontic infections [34], or more general organ pathology [35]. The oral cavity and the gut are usually
colonized with balanced quantities of such opportunistic pathogens. The opportunistic/pathogenic
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features limit or eliminate their potential utilization as probiotic agents; but do not exclude the use of
the purified enzymes.
In this vein, safety is a major concern when live bacteria are considered as probiotic for CeD.
The search for an effective and non-toxic probiotic for the treatment of CeD has become a topic of high
importance for the celiac community and health care providers [4,22,26,36]. Food-grade proteases
capable of detoxifying moderate quantities of dietary gluten could help mitigate this problem [24,26].
In search for alternatives, natural human gluten-degrading microbial colonizers, in a live form when
harmless, or neutralized with ethanol treatment, could potentially offer the basis for the development of
new and low-cost therapeutics for CeD. In the present study, we developed a method to abolish toxicity
associated with the live cells without affecting gluten-degrading activities. The bacterial treatment
with 70% ethanol killed the live bacteria, retained gliadin degrading activity, and the added ethanol
can be fully removed by lyophilization. While ethanol treatment will not neutralize cell-associated
lipopolysaccharide, or certain exotoxins or endotoxins, it abolishes cell viability, colonization capacity,
and potential of active transfer of virulence factors and antibiotic resistance genes to other bacteria.
Our study also shows that a range of antibiotics (Supplemental Figure S2) effectively abolished the
viability of four gluten-degrading microbial strains. Thus, there are several strategies to safely apply
Rothia bacteria, e.g., in an ethanol-killed formulation, to patients with CeD, and/or to treat Rothia
infections effectively with antibiotics, should any infection occur.
We previously identified the gliadin-degrading enzyme from R. mucilaginosa [15]. In the present
study, we identified the R. aeria enzyme a subtilisin-like serine protease belonging to the S8 peptidase
family. These subtilisins can rapidly hydrolyze gliadin immunogenic epitopes, efficiently degrade
the immunogenic gliadin-derived 33-mer peptide, and can be considered promising new candidates
for enzyme therapeutics in CeD [26]. The R. aeria protein identified in the gliadin degrading
protein band matched with BAV86562.1. This protein was seemingly incorrectly annotated as a
glycerol-3-phosphate-ABC transporter in the NCBI data base, since it lacks the structural features of
an ABC transporter. ABC transporters are characterized by two transmembrane domains and two
nucleotide-binding domains, containing the signature sequence LSGGQ, which is directly involved
in nucleotide binding [37]. BAV86562.1 does not contain these domains and the LSGGQ sequence.
In contrast, it does contain the D-H-S (Asp-His-Ser) catalytic amino acid triad with flanking regions
characteristic for the subtilisin family of proteases. Thus, BAV86562.1 expressed by R. aeria is a S8
subtilisin peptidase and not an ABC transporter.
Peptidase S8 belongs to the subtilases superfamily, a group of enzymes which were first isolated
from Bacillus subtilis, a species inhabiting, e.g., soils [38]. Since Bacillus species are also present in
the oral cavity, like Rothia species [8], we compared the R. aeria and B. subtilis gliadin-degrading
activities. R. aeria was found to have a higher activity than B. subtilis. More importantly, R. aeria, but not
B. subtilis, exerted appreciable activity at an acidic pH, i.e., gastric pH 3.0, that is found 1 h after food
ingestion [39]. This clearly qualifies the R. aeria subtilisin that we identified in this study to serve as
an enzyme source that can degrade immunogenic gluten epitopes in the stomach, before they reach
the duodenum to elicit intestinal inflammation in patients with CeD. Since the R. aeria enzyme can be
cloned and expressed in high doses, and since it may be suitable for further optimization towards even
higher gluten degrading efficacy in the stomach, clinical applications should be explored.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/12/3724/s1.
Supplemental Figure S1. Enzymatic degradation of gliadins in mouse chow in vitro detected by immunoblotting;
Supplemental Figure S2. MIC Susceptibility of two Rothia species to antimicrobics; Supplemental Figure S3.
Amino acid sequence of R. aeria BAV86562.1.
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